questionsmedicales.fr
Bactéries
Proteobacteria
Gammaproteobacteria
Vibrionaceae
Vibrio
Vibrio : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vibrio : Questions médicales les plus fréquentes",
"headline": "Vibrio : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vibrio"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vibrionaceae",
"url": "https://questionsmedicales.fr/mesh/D014737",
"about": {
"@type": "MedicalCondition",
"name": "Vibrionaceae",
"code": {
"@type": "MedicalCode",
"code": "D014737",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio alginolyticus",
"alternateName": "Vibrio alginolyticus",
"url": "https://questionsmedicales.fr/mesh/D044149",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio alginolyticus",
"code": {
"@type": "MedicalCode",
"code": "D044149",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.030"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae",
"alternateName": "Vibrio cholerae",
"url": "https://questionsmedicales.fr/mesh/D014734",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae",
"code": {
"@type": "MedicalCode",
"code": "D014734",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae non-O1",
"alternateName": "Vibrio cholerae non-O1",
"url": "https://questionsmedicales.fr/mesh/D044163",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae non-O1",
"code": {
"@type": "MedicalCode",
"code": "D044163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O1",
"alternateName": "Vibrio cholerae O1",
"url": "https://questionsmedicales.fr/mesh/D041241",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O1",
"code": {
"@type": "MedicalCode",
"code": "D041241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O139",
"alternateName": "Vibrio cholerae O139",
"url": "https://questionsmedicales.fr/mesh/D041242",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O139",
"code": {
"@type": "MedicalCode",
"code": "D041242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Vibrio mimicus",
"alternateName": "Vibrio mimicus",
"url": "https://questionsmedicales.fr/mesh/D044164",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio mimicus",
"code": {
"@type": "MedicalCode",
"code": "D044164",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio parahaemolyticus",
"alternateName": "Vibrio parahaemolyticus",
"url": "https://questionsmedicales.fr/mesh/D014736",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio parahaemolyticus",
"code": {
"@type": "MedicalCode",
"code": "D014736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.590"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio vulnificus",
"alternateName": "Vibrio vulnificus",
"url": "https://questionsmedicales.fr/mesh/D041261",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio vulnificus",
"code": {
"@type": "MedicalCode",
"code": "D041261",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vibrio",
"alternateName": "Vibrio",
"code": {
"@type": "MedicalCode",
"code": "D014733",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jaime Martinez-Urtaza",
"url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Jessica L Jones",
"url": "https://questionsmedicales.fr/author/Jessica%20L%20Jones",
"affiliation": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136."
}
},
{
"@type": "Person",
"name": "William C Walton",
"url": "https://questionsmedicales.fr/author/William%20C%20Walton",
"affiliation": {
"@type": "Organization",
"name": "2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA."
}
},
{
"@type": "Person",
"name": "Julia C van Kessel",
"url": "https://questionsmedicales.fr/author/Julia%20C%20van%20Kessel",
"affiliation": {
"@type": "Organization",
"name": "Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu."
}
},
{
"@type": "Person",
"name": "Blake Ushijima",
"url": "https://questionsmedicales.fr/author/Blake%20Ushijima",
"affiliation": {
"@type": "Organization",
"name": "Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Ceftazidime/avibactam-induced severe neutropenia: A case report.",
"datePublished": "2023-07-24",
"url": "https://questionsmedicales.fr/article/37427878",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bcp.15844"
}
},
{
"@type": "ScholarlyArticle",
"name": "Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.",
"datePublished": "2022-07-26",
"url": "https://questionsmedicales.fr/article/35891616",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/wsbm.1571"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing",
"datePublished": "2023-03-01",
"url": "https://questionsmedicales.fr/article/36902196",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24054767"
}
},
{
"@type": "ScholarlyArticle",
"name": "Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients.",
"datePublished": "2023-06-08",
"url": "https://questionsmedicales.fr/article/37301439",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cmi.2023.06.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Simultaneous determination of ceftazidime and pyridine in human plasma by LC-UV.",
"datePublished": "2023-02-26",
"url": "https://questionsmedicales.fr/article/36858005",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpba.2023.115319"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Bactéries",
"item": "https://questionsmedicales.fr/mesh/D001419"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020560"
},
{
"@type": "ListItem",
"position": 4,
"name": "Gammaproteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020563"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vibrionaceae",
"item": "https://questionsmedicales.fr/mesh/D014737"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014733"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vibrio - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vibrio",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vibrio",
"description": "Comment diagnostiquer une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes tests sérologiques sont-ils utiles ?\nPeut-on diagnostiquer Vibrio par PCR ?\nQuels symptômes orientent vers un diagnostic de Vibrio ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vibrio",
"description": "Quels sont les symptômes d'une infection à Vibrio ?\nLa diarrhée est-elle toujours présente ?\nLes infections à Vibrio causent-elles de la fièvre ?\nY a-t-il des symptômes graves associés ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vibrio",
"description": "Comment prévenir les infections à Vibrio ?\nLe lavage des mains est-il important ?\nLes vaccinations existent-elles contre Vibrio ?\nFaut-il éviter certains aliments ?\nLes voyages augmentent-ils le risque d'infection ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vibrio",
"description": "Quel est le traitement principal pour Vibrio ?\nQuels antibiotiques sont efficaces contre Vibrio ?\nLa réhydratation est-elle toujours nécessaire ?\nLes traitements sont-ils différents selon le type de Vibrio ?\nLes probiotiques aident-ils dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vibrio",
"description": "Quelles complications peuvent survenir avec Vibrio ?\nLa déshydratation est-elle une complication fréquente ?\nLes infections à Vibrio peuvent-elles être mortelles ?\nY a-t-il des risques pour les personnes immunodéprimées ?\nLes infections cutanées sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vibrio",
"description": "Quels sont les principaux facteurs de risque pour Vibrio ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection ?\nLes personnes vivant près de l'eau sont-elles plus exposées ?\nLes voyages dans des zones endémiques sont-ils risqués ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection à Vibrio ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour identifier Vibrio ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture et des tests biochimiques spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les tests sérologiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques ne sont généralement pas utilisés pour Vibrio."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer Vibrio par PCR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons."
}
},
{
"@type": "Question",
"name": "Quels symptômes orientent vers un diagnostic de Vibrio ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection à Vibrio ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre."
}
},
{
"@type": "Question",
"name": "La diarrhée est-elle toujours présente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio causent-elles de la fièvre ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes graves associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections à Vibrio ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains."
}
},
{
"@type": "Question",
"name": "Le lavage des mains est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes."
}
},
{
"@type": "Question",
"name": "Les vaccinations existent-elles contre Vibrio ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains aliments ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'infection ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour Vibrio ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels antibiotiques sont efficaces contre Vibrio ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "La réhydratation est-elle toujours nécessaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents selon le type de Vibrio ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection."
}
},
{
"@type": "Question",
"name": "Les probiotiques aident-ils dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Vibrio ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale."
}
},
{
"@type": "Question",
"name": "La déshydratation est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio peuvent-elles être mortelles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour les personnes immunodéprimées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées sont à risque accru de complications graves."
}
},
{
"@type": "Question",
"name": "Les infections cutanées sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour Vibrio ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio."
}
},
{
"@type": "Question",
"name": "Le diabète augmente-t-il le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut augmenter le risque d'infections graves à Vibrio."
}
},
{
"@type": "Question",
"name": "Les personnes vivant près de l'eau sont-elles plus exposées ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones endémiques sont-ils risqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection."
}
}
]
}
]
}
Ceftazidime/avibactam is an important option for the treatment of infections caused by multidrug-resistant gram-negative bacteria. Haematological abnormalities are rare adverse events. We describe a c...
Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β-lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the...
The continuous spread of carbapenem-resistant...
Peritonitis is a serious complication in patients undergoing automated peritoneal dialysis (APD) that increases morbidity and frequently disqualifies patients from the peritoneal dialysis programme. C...
A prospective, open-label PK study was conducted on eight patients undergoing APD. CAZ/AVI was administered as a single intravenous dose of 2 g/0.5 g over 120 minutes. APD cycles were initiated 15 hou...
PK profiles of both drugs in plasma and PDS were similar, indicating that the two drugs are well suited for a fixed-dose combination. A two-compartment model best described the PK of both drugs. A sin...
On the basis of PTA simulations, a dose of 750/190 mg CAZ/AVI would be sufficient to treat plasma and peritoneal fluid infections in patients undergoing APD....
A sensitive, accurate and precise liquid chromatography (LC) method for the simultaneous determination of ceftazidime and pyridine in human plasma has been developed and validated. Acetonitrile (ACN) ...
This study assessed the...
Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its resistance by analyzing gram-negative bacteria isolated from various patient samples....
Between March and November 2020, 1119 gram-negative bacteria strains were isolated from patient samples in Acıbadem Healthcare Group hospitals; ceftazidime-avibactam susceptibility results were evalua...
Male patients made up 52% (n = 581) of the study's total patient population, and they averaged 55.5 ± 24.9 years old. Of 1119 gram-negative strains culture and antibiogram, 1023 (91.4%) were sensitive...
The resistance rate of ceftazidime-avibactam was found to be 8.6%, and it was thought that resistant strains produced metallo-ß-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pse...
In the battle against multidrug-resistant bacterial infections, ceftazidime- avibactam (CZA) stands as a pivotal defense, particularly against carbapenemresistant (CR) Gram-negative pathogens. However...
This research focuses on the genomic characterization of CR- and CZA-resistant...
Our findings revealed a notable prevalence of blaNDM in all...
The study underscores NDM carbapenemases as a paramount resistance mechanism in Lebanon,jeopardizing critical last-resort treatments. It also illuminates the role of varied sequence types and mobile g...
This work aimed to describe the in vitro performance of the combined activity of ceftazidime-avibactam (CZA) plus aztreonam (ATM) against carbapenemase-producing Enterobacterales (CPE)....
We studied 44 CPE clinical isolates: NDM-1 (31), KPC-2 (5), KPC-3 (3), VIM-2 (2), NDM-1+KPC-2 (2), and OXA-48 (1). The efficacy of CZA in combination with were determined by two methods: (i) Kirby-Bau...
All isolates were carbapenem-resistant, 14 were resistant to CZA and ATM, 15 were only CZA resistant, 12 were only ATM resistant, and three were susceptible to both. 34/44 isolates presented positive ...
This method is available to clinical laboratories and would provide valuable information to guide the treatment of infections with CZA and ATM. In this sense, the use of CZA together with ATM is a pot...
First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistan...